Pathstone Holdings LLC Reduces Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Pathstone Holdings LLC lowered its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 1.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,219 shares of the medical equipment provider's stock after selling 709 shares during the quarter. Pathstone Holdings LLC's holdings in Intuitive Surgical were worth $25,169,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of ISRG. Capital Investment Advisors LLC increased its holdings in shares of Intuitive Surgical by 15.6% during the fourth quarter. Capital Investment Advisors LLC now owns 899 shares of the medical equipment provider's stock valued at $469,000 after acquiring an additional 121 shares in the last quarter. Miracle Mile Advisors LLC increased its holdings in shares of Intuitive Surgical by 7.9% during the fourth quarter. Miracle Mile Advisors LLC now owns 1,948 shares of the medical equipment provider's stock valued at $1,017,000 after acquiring an additional 143 shares in the last quarter. Signal Advisors Wealth LLC increased its holdings in shares of Intuitive Surgical by 12.2% during the fourth quarter. Signal Advisors Wealth LLC now owns 1,594 shares of the medical equipment provider's stock valued at $832,000 after acquiring an additional 173 shares in the last quarter. Accurate Wealth Management LLC increased its holdings in shares of Intuitive Surgical by 6.7% during the fourth quarter. Accurate Wealth Management LLC now owns 5,978 shares of the medical equipment provider's stock valued at $3,273,000 after acquiring an additional 373 shares in the last quarter. Finally, SeaCrest Wealth Management LLC increased its holdings in Intuitive Surgical by 2.2% in the 4th quarter. SeaCrest Wealth Management LLC now owns 1,982 shares of the medical equipment provider's stock worth $1,035,000 after buying an additional 42 shares during the period. Institutional investors and hedge funds own 83.64% of the company's stock.

Intuitive Surgical Price Performance

ISRG stock traded up $3.32 during trading on Friday, hitting $563.60. The stock had a trading volume of 1,422,176 shares, compared to its average volume of 1,644,552. The stock has a market capitalization of $202.00 billion, a P/E ratio of 87.93, a PEG ratio of 5.85 and a beta of 1.70. The company's 50-day moving average price is $505.22 and its two-hundred day moving average price is $536.61. Intuitive Surgical, Inc. has a twelve month low of $395.60 and a twelve month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 EPS for the quarter, topping the consensus estimate of $1.71 by $0.10. Intuitive Surgical had a return on equity of 14.55% and a net margin of 27.81%. The firm had revenue of $2.25 billion during the quarter, compared to analysts' expectations of $2.19 billion. During the same period in the previous year, the business earned $1.50 earnings per share. As a group, sell-side analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ISRG. UBS Group increased their price target on shares of Intuitive Surgical from $500.00 to $560.00 and gave the stock a "neutral" rating in a report on Monday, January 27th. JPMorgan Chase & Co. increased their price target on shares of Intuitive Surgical from $575.00 to $675.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Wells Fargo & Company increased their price target on shares of Intuitive Surgical from $630.00 to $687.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Jefferies Financial Group increased their price target on shares of Intuitive Surgical from $475.00 to $575.00 in a report on Monday, January 27th. Finally, Truist Financial lowered their price objective on Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $598.95.

Insider Activity at Intuitive Surgical

In related news, EVP Brian Edward Miller sold 8,900 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $485.07, for a total value of $4,317,123.00. Following the completion of the transaction, the executive vice president now directly owns 5,758 shares of the company's stock, valued at approximately $2,793,033.06. This represents a 60.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Fredrik Widman sold 810 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $573.78, for a total value of $464,761.80. Following the completion of the transaction, the vice president now directly owns 473 shares of the company's stock, valued at approximately $271,397.94. This represents a 63.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,700 shares of company stock valued at $16,865,621. 0.70% of the stock is owned by insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.